Hydrea

Hydrea is an oral tablet formulation that contains the active ingredient hydroxycarbamide. It is marketed in the European Union as a prescription antineoplastic agent used to manage certain myeloproliferative disorders. As a ribonucleotide reductase inhibitor, Hydrea interferes with DNA synthesis, which helps control abnormal cell proliferation. The medication is supplied without a specific strength in this description, and it requires a physician’s order for treatment.

Hydrea is indicated for several hematologic conditions where abnormal cell growth requires cytoreductive therapy.

- Chronic myeloid leukemia (CML) in patients who are resistant or intolerant to first‑line tyrosine‑kinase inhibitors. - Sickle cell disease to reduce the frequency of painful vaso‑occlusive crises. - Polycythemia vera for controlling elevated red blood cell mass and preventing thrombosis. - Essential thrombocythemia to lower platelet counts and lower thrombotic risk. - Myelodysplastic syndromes when disease‑modifying therapy is indicated. - Certain solid‑tumor protocols where hydroxycarbamide is used as a radiosensitizer.

Hydroxycarbamide may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common: - Nausea, vomiting or loss of appetite. - Fatigue and generalized weakness. - Mild skin discoloration or hyperpigmentation. - Low white blood cell counts (leukopenia) leading to increased infection risk. - Elevated liver enzymes indicating mild hepatic irritation. - Mouth sores or oral mucositis. - Transient hair thinning or alopecia.

Serious: - Severe bone marrow suppression causing anemia, neutropenia, or thrombocytopenia. - Acute renal failure or significant rise in serum creatinine. - Life‑threatening allergic reactions such as anaphylaxis. - Pulmonary toxicity including interstitial pneumonitis. - Secondary malignancies, although rare, have been reported. - Severe gastrointestinal bleeding or ulceration.

Before initiating Hydrea, several precautionary measures should be reviewed to minimize risks and ensure safe use.

- Perform baseline complete blood count and liver function tests, and repeat regularly during therapy. - Avoid use in pregnant women; the drug is classified as pregnancy category D due to fetal toxicity. - Use only when the benefits outweigh risks in patients with pre‑existing renal impairment. - Monitor for signs of infection, as neutropenia can develop rapidly. - Counsel patients to use effective contraception during treatment and for several weeks after discontinuation. - Adjust dose or discontinue if severe bone‑marrow suppression occurs. - Review concomitant medications that may potentiate myelosuppression.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or safety profile.

Avoid: - Concurrent use with other myelosuppressive agents such as azacitidine or chemotherapy drugs, which may exacerbate bone‑marrow toxicity. - Combining with high‑dose folic‑acid antagonists that could intensify cytopenias.

Use with caution: - NSAIDs or aspirin, which may increase the risk of gastrointestinal bleeding. - Allopurinol, as it can alter hydroxycarbamide metabolism and raise plasma levels. - Live vaccines, because immunosuppression may reduce vaccine effectiveness. - Antacids containing aluminum or magnesium, which might affect oral absorption.